

1. Record Nr.	UNINA9910865283803321
Autore	Dlamini Zodwa
Titolo	Overcoming Breast Cancer Therapy Resistance : From Mechanisms to Precision and AI-Powered Approaches
Pubbl/distr/stampa	Cham : , : Springer International Publishing AG, , 2024 ©2024
ISBN	9783031528606 9783031528590
Edizione	[1st ed.]
Descrizione fisica	1 online resource (390 pages)
Disciplina	616.9944906
Soggetti	Breast Neoplasms Drug Resistance
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Preface -- Contents -- About the Editor -- Part I: Understanding Breast Cancer and Drug Resistance -- Introduction to Breast Cancer and Drug Resistance -- Introduction -- Epidemiology and Classification of Breast Cancer -- Common Treatments and Resistance to these Therapies -- The Prevalence of Resistance in Breast Cancer -- Overcoming Resistance to Common Therapies -- Revolutionary Approaches to Reverse Resistance in Breast Cancer -- Limitations to the Development in Implementation of Novel Strategies to Overcome Resistance in Breast Cancer -- Conclusion -- References -- Mechanisms of Drug Resistance in Breast Cancer -- Introduction -- Treatment -- Genetic and Molecular Mechanisms Contributing to Drug Resistance -- Molecular Pathways -- Hormone Receptor Pathway -- Epidermal Growth Factor Receptor (EGFR) Pathway -- Ras/Raf/MAPK Pathway -- PI3K/Akt/mTOR Pathway -- IL-6/JAK/STAT Pathway -- WNT/-Catenin Signaling Pathway -- Hedgehog Signaling Pathway -- Notch Signaling Pathway -- Aryl Hydrocarbon Receptor -- Inducible Nitric Oxide Synthase -- Preclinical and Clinical Trials in Breast Cancer -- Challenges and Limitations in Targeting Molecular Pathways -- Conclusion -- References -- Part II: Drug Resistance in Breast Cancer Treatment -- Resistance to Targeted Therapy in Breast Cancer -- Introduction -- Drug-Resistant Breast Cancer -- Potential Targeted

Therapies Directed At Various Molecular Pathways -- Aryl Hydrocarbon Receptor -- Inducible Nitrate Oxide Synthase -- PI3K/Akt/mTOR Pathway -- Poly (ADP-Ribose) Polymerase -- Cyclin-Dependent Kinase 4/6 -- Wnt/-Catenin Pathway -- Epidermal Growth Factor Receptor -- Human Epidermal Growth Factor Receptor-2 (HER-2) -- The Vascular Endothelial Growth Factor -- Hormone Receptors as Targets of Therapy -- Pharmacologic Mechanisms of Target Therapy Agents -- Small Molecules -- Monoclonal Antibodies.

Immunotherapeutic Cancer Vaccines -- Gene Therapy -- Strategies to Overcome Resistance to Targeted Therapies -- Limitations of Targeted Therapy in Breast Cancer -- Conclusion -- References -- Resistance to Immunotherapy in Breast Cancer -- Introduction -- Classification of Immunotherapy Resistance to Breast Cancer Immunotherapies -- Current Approaches in Breast Cancer Immunotherapeutic Interventions -- Immune Checkpoint Inhibitors -- Adoptive Cell Therapy -- Tumor-Infiltrating Lymphocytes (TILs) Therapy -- Chimeric Antigen Receptor (CAR) T Cell Therapy -- Engineered T Cell Receptor Therapy -- Natural Killer Cell Therapy -- Bispecific Antibody Therapy -- Combinations of Cancer Immunotherapy in Breast Cancer -- Overcoming Immune Resistance and Enhancing Responses -- Challenges and Limitations -- Conclusion and Future Perspectives -- References -- Resistance to Endocrine Therapy in Breast Cancer -- Introduction to Endocrine Therapy -- Hormone Receptor Testing -- Endocrine Therapy -- Aromatase and Aromatase Inhibitors -- Selective Estrogen Receptor Modulators -- Selective Estrogen Receptor Downregulators -- Endocrine Therapy Resistance -- Epigenetic Changes -- Somatic Changes -- Tumor Microenvironment -- Overcoming Endocrine Therapy Resistance -- Inhibition of Downstream Signaling Pathways -- Novel Endocrine Therapies -- Combinatorial Approaches to Enhance Endocrine Therapy Response -- Challenges and Limitations of Endocrine Therapy -- Conclusion -- References -- Resistance to Chemotherapy in Breast Cancer -- Introduction -- Overview of Breast Cancer and Its Prevalence -- Mechanisms of Chemotherapy Resistance in Breast Cancer -- Genetic Factors Influencing Chemoresistance in Breast Cancer -- Multidrug Resistance Gene (MDR1) -- Twist-Related Protein 1 Gene (TWIST1) -- Epigenetic Factors Influencing Chemoresistance -- MicroRNAs.

Cancer Stem Cells and Their Contribution to Treatment Resistance -- Epithelial to Mesenchymal Transition (EMT) -- Tumor Microenvironment and Chemoresistance -- Tumor Hypoxia -- Tumor Tissue pH -- Chemotherapy Agent and Chemoresistance -- Elevated Drug Efflux As a Resistance Mechanism -- Novel Strategies to Overcome Chemotherapy Resistance in Breast Cancer -- Novel Drug Delivery Systems -- Exosome-Based Drug Delivery Systems -- Gene Therapy -- Combination Therapy -- The Use of Immunotherapy -- Immune Checkpoint Inhibitors (ICIs) -- Cyclin-Dependent Kinase 4/6 Inhibitors -- Breast Cancer Stem Cell-Directed Therapy -- Autophagy Modulation -- Limitations of Exosome-Based Drug Delivery Systems -- Conclusion and Future Perspectives -- References -- Part III: Innovative Approaches and Strategies to Overcome Drug Resistance -- Unraveling the Impact of Aberrant Splicing Machinery on Drug Resistance in Breast Cancer: Identifying Targets for Innovative Counteractive Strategies -- Introduction -- A Summary of Splicing Alterations in Breast Cancer -- Pathways Involved in Drug Resistance Affected By Aberrant Splicing -- Splicing Events in Pathways Involved in Anti-estrogen Therapy -- Inflammation -- Receptor Tyrosine Kinase Pathways -- Unfolded Protein Response -- Metabolic Pathways -- Apoptosis Pathways -- The Cell Cycle ECT -- DNA Damage Repair BRCA1 -- CDK4/6 Inhibitors --

Dysregulation of Splicing Machinery in Drug-Resistant Breast Cancer -- SF3b -- HnRNP -- PRP4K -- TRA2 -- Counteractive Strategies -- Therapeutic Strategies Targeting the Spliceosome -- Limitations to Targeting Splicing for Therapeutic Interventions or As Biomarkers -- Conclusion -- References -- Unveiling Strategies to Conquer Virus-Induced Breast Cancer Drug Resistance -- Introduction -- Human Papillomavirus (HPV) -- The Mammary Tumor Viruses (MMTV) -- Cytomegalovirus (CMV). Epstein-Barr Virus (EBV) -- Measles Virus -- HIV -- Overview of Drug Chemoresistance in Virus-Associated Cancers -- Mechanisms of Chemoresistance in Virus-Associated Breast Cancer -- Drug Efflux-Mediated Chemoresistance in Virus-Associated Cancer -- Virus-Mediated Chemoresistance by Regulation of Apoptosis -- Virus-Mediated Cancer Chemoresistance Through Upregulation of the Glycolysis Pathway -- Exosome and Autophagy-Mediated Cancer Chemoresistance -- Oncogenic Signaling Pathways -- Mutagenic Role of Antiviral Factors in Breast Cancer -- Oncolytic Viruses in Breast Cancer Treatment (Viral Oncotherapy) -- Oncolytic Viruses As Immunotherapeutics -- Combination of Virotherapy and Immunotherapy -- Effective Strategies to Overcome Virus-Induced Drug Resistance -- Ongoing and Future Research -- Next-Generation Sequencing Technology with Pathogen Discovery -- Limitations of Virotherapy for Breast Cancer Treatment -- Conclusion and Recommendations -- References -- Harnessing the Power of Natural Products in Overcoming Drug Resistance in Breast Cancer -- Introduction -- Mechanisms of Action Exhibited By Natural Products in Overcoming Drug Resistance -- Modulation of Apoptosis Pathways -- Inhibition of Drug Efflux Pumps -- Modulation of Signaling Pathways -- Targeting Cancer Stem Cells -- The Role of Natural Products As Chemosensitizers in Reversing Multidrug Resistance in Breast Cancer -- The Transition of Natural Compounds from the Laboratory to Clinical Settings in Breast Cancer Treatment -- Bioavailability Challenges -- Interaction with Conventional Therapies -- Clinical Trials and Effectiveness -- Cannabis As a Natural Cancer Therapy -- Conclusion -- References -- Revolutionizing Breast Cancer Treatment: Harnessing the Power of Artificial Intelligence in Overcoming Drug Resistance -- Introduction. AI-Driven Drug Discovery and Design with Enhanced Efficacy Against Drug-Resistant Breast Cancer -- The Role of AI in Minimizing the Risk of Drug Resistance in Personalized Breast Cancer Therapies -- AI-Based Models That May Be Employed for Personalized Breast Cancer Therapy -- AI and Anticancer Drug Development (Machine Learning and Deep Learning in Anticancer Drug Development) -- AI-Enhanced Predictive Models and Early Detection of Drug Resistance in Adapting Treatment Strategies to Overcome Drug Resistance in Breast Cancer -- Integration of AI-Enhanced Technology and Clinicopathological Features to Predict Breast Cancer Recurrence -- Integration of AI with Immunohistopathological Records Datasets to Predict Metastasis -- Integration of AI with Biomarkers Signatures to Predict Drug Resistance in Breast Cancer -- Challenges and Limitations of Harnessing the Power of AI in Drug Design, Early Detection, and Overcoming Drug Resistance in Breast Cancer -- Concluding Remarks -- References -- Part IV: Future Directions and Advancements in Overcoming Drug Resistance -- The Microbiome: A New Frontier in Overcoming Drug Resistance in Breast Cancer -- Introduction -- Gut Microbiota in Innate Immunity and Normal Physiology -- Dysbiosis of the Microbiota of the Gut Microbiome and Diseases -- Dysbiosis of the Breast and Gut Microbiome and Pathogenesis of Breast Cancer --

Elevated Estrogen Levels -- Chronic Inflammation -- Obesity -- Short-Chain Fatty Acids and Breast Cancer Carcinogenesis -- Management of Breast Cancer -- Influence of Management Options for Breast Cancer on the Gut Microbiota -- Microbiome, Dysbiosis, and Breast Cancer -- Dysbiosis and Drug Resistance in Breast Cancer -- Management of Dysbiosis in Drug-Resistant Breast Cancer -- Physical Exercise -- Dietary Management -- Mediterranean Diet -- Ketogenic Diet. Probiotics, Prebiotics, Synbiotics, and Postbiotics.
